Clinical Trial: Study of CMP-002 in Participants With SYNGAP1-Related Disorder

U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935135) titled 'Study of CMP-002 in Participants With SYNGAP1-Related Disorder' on Oct. 30.

Brief Summary: The primary purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of CMP-002 in participants with SYNGAP1-related disorder.

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Nervous System Disease

Intervention: DRUG: CMP-002

CMP-002 is an antisense oligonucleotide that will be administered by IT injection.

OTHER: Sham-prick

The sham-prick procedure involves no injection/puncture or penetration of the dura, but only a skin prick with a needle.

Recruitment Status: NOT_YET_RECRUITING

Sponso...